Datum: 07.09.2019
Ort: Ärztehaus, An der Petrikirche 1, 38100 Braunschweig
 
Sehr geehrte Frau Kollegin,
sehr geehrter Herr Kollege,
 
wir möchten Sie gern auch dieses Jahr wieder zu unserer Jahrestagung herzlich einladen.  Für 2019 haben wir drei interessante Sitzungen für Sie zusammengestellt; für die I. Sitzung haben wir das Thema Klappenerkrankungen ausgewählt, die II. und III. Sitzung widmen sich Themen, die für den klinischen Alltag wichtig sind.

Unsere 23. wissenschaftliche Jahrestagung mit den Themen:
 
AKTUELLE KARDIOLOGIE & INTERESSANTE KASUISTIKEN
 
findet in diesem Jahr wie gewohnt in Braunschweig zusammen mit eingeladenen Gästen aus Vietnam in Zusammenarbeit mit der Ärztekammer Niedersachsen Bezirksstelle Braunschweig und dem Ärzteverein Braunschweig statt.  Wir möchten Sie hiermit herzlich nach Braunschweig einladen und freuen uns auf Ihr Kommen. 
Ganz besonders bei dieser Jahrestagung freuen wir uns sehr über die erste Teilnahme von Studierenden der Vietnamese German Faculty of Medicine (VGFM, ein Förderprojekt des DVFK), die zurzeit im Klinikum Braunschweig, Wolfsburg,  Wolfenbüttel und Herzogin Elisabeth Hospital Braunschweig ihr praktisches Jahr absolvieren.

Mit freundlichen Grüßen
Prof. Dr. Rolf Engberding     Prof. Dr. Si Huyen Nguyen    Prof. Dr. Volker Klauss
       Wolfsburg                                    HCMC/Helmstedt                      München
 
Diese Fortbildung ist bei der Landesärztekammer Niedersachsen mit 4 CME Punkten anerkannt.

​PROGRAMM:

8.30 Eröffnung:       
S.H. Nguyen, Präsident des DVFK / Helmstedt 
R. Engberding, Präsident GVAC

8:45 Grußwort:   
M. C. Renneberg, Vize-Präsidentin ÄKN und Vorsitzende der Ärztekammer Bezirksstelle Braunschweig
 
I. Sitzung: Klappenerkrankungen
Vorsitz: SH Nguyen (Helmstedt), W. Harringer (Braunschweig)
 
09:00    Diagnostik und Therapie der Mitralklappeninsuffizienz
              B. Gerecke (Göttingen)
09:20    Aortenstenose: aktuelle Standards in Diagnostik und Therapie  
              W. Fehske (Köln)
09:40    Chirurgische Therapieoptionen bei Aortenstenose
              M. Anssar / W. Harringer (Braunschweig)
 
10:00    Pause
 
II. Sitzung: Interessante Kasuistiken
Vorsitz: J. Tebbenjohanns (Hildesheim), W. Fehske (Köln)
 
10:20    Myokardhypertrophie
              I. Kruck (Berlin)
10:40    Akuter Myokardinfarkt
              C. Fleischmann (Wolfsburg)
11:00     Interessante Kasuistik aus Hildesheim
              J. Tebbenjohanns (Hildesheim)
 
III. Sitzung:  Aktuelle Kardiologie im klinischen Alltag
Vorsitz: R. Becker (Wolfsburg), W. Diederich (Helmstedt)
 
11:20    Kardiale Sarkoidose
              B. Schneider (Lübeck)
11.40    Therapie der chronischen Herzinsuffizienz-Update 2019
              B. Gerecke (Göttingen)              
12.00    Ablation von Vorhofflimmern: neue Techniken und Strategien
              D.Q. Nguyen (Köln)   
 
12:20    Diskussionsrunde 
12:40    Schlusswort
              B. Gerecke (Göttingen)
                              
              Im Anschluss weitere Diskussionen bei einem Imbiss
 
14:00    DVFK-Mitgliederversammlung  

          REFERENTEN UND GÄSTE: 

• Dr. Marcel Anssar, Herz-, Thorax- und Gefäßchirurgie, Klinikum Braunschweig
• Prof. Dr. Rüdiger Becker, I. Medizinische Klinik, Klinikum Wolfsburg
• Dr. W. Diederich, Med. Klinik II, Kardiologie, HELIOS St. Marienberg Klinik Helmstedt
• Prof. Dr. Rolf Engberding, AMO Medizinisches Versorgungszentrum/Klinikum Wolfburg/Vietnamese German Academy for Science and Education in Cardiology and Cardiovascular Surgery (VGAC)
• PD Dr. Wolfgang Fehske, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln
• Dr. Claus Fleischmann, I. Medizinische Klinik, Klinikum Wolfsburg
• Dr. Birgit Gerecke, Universitätsmedizin Göttingen, Universitäres Herzzentrum
• PD Dr. Wolfgang Harringer, Herz-Thorax- und Gefäßchirurgie, Klinikum Braunschweig
• Prof. Dr. Volker Klauss, Kardiologie Innenstadt, München
• Dr. Irmtraut Kruck, Kardiologie, Charité Berlin
• Dr. Dinh Quang Nguyen, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln
• Dr. Si Huyen Nguyen, Prof. für Innere Medizin und Intensivmedizin der Med. Universität PNT, HCM City, Med. Klinik II, Kardiologie, HELIOS St. Marienberg Klinik Helmstedt
• Dr. Birke Schneider, Lübeck
• Prof. Dr. Jürgen Tebbenjohanns, Kardiologie, Helios Klinikum Hildesheim

SPONSOREN DER TAGUNG:
Bayer Vital GmbH (1000 €), Daiichi-Sankyo Deutschland GmbH (750 €), Novartis Pharma GmbH (700 €) 
Stand 60.08.19
          

HERZLICHE EINLADUNG
ZU UNSERER 22. DVFK-JAHRESTAGUNG IN BRAUNSCHWEIG 
 
Für Ihre Teilnahme keine Anmeldung erforderlich!
Fortbildungsanerkennung: 4 CME Punkte bei Landesärztekammer Niedersachsen!
 
Datum:                       01.09.2018
Ort:                              Ärztehaus, An der Petrikirche 1, 38100 Braunschweig
               
KARDIOMYOPATHIEN Update 2018 &
KARDIOLOGIE IM KLINISCHEN ALLTAG
 
PROGRAMM:
8.30 Eröffnung:             S.H. Nguyen, Präsident des DVFK / Helmstedt
8:45 Grußwort:             D.V. Phuoc, President of the Vietnam Heart Association HCMC
 
I. Sitzung:      Kardiomyopathien Update 2018
Vorsitz:             J. Tebbenjohanns (Hildesheim) , W. Harringer (Braunschweig)
 
09:00                Dilatative Kardiomyopathie und Noncompaction Kardiomypathie
                          B. Gerecke (Göttingen)
09:30                Hypertrophe Kardiomyopathie
                          H. Seggewiß (Schweinfurt)
09:50                Arrhythmogene rechtsventrikuläre Kardiomyopathie
                          J. Tebbenjohanns (Hildesheim)
10:10                Chirurgische Therapieoptionen bei Kardiomyopathien
                          M. Anssar / W. Harringer (Braunschweig)
 
10:30                Pause
 
II. Sitzung:     Kardiologie im klinischen Alltag
Vorsitz:             R. Becker (Wolfsburg) / W. Fehske (Köln)
 
11.00                Interessante Kasuistik: ein Patient mit Lungenembolie
                          T. Budde (Essen)         
11.20                Echokardiographische Beurteilung der Trikuspidalklappe
                          W. Fehske (Köln)
11:40                Moderne Device-Therapie – „State of the Art”
                          S. Winter (Köln)
12:00                Katheterablation bei Vorhofflimmern – aktuelle Studienlage             
                          D.Q. Nguyen (Köln)      
12:20                Periprozedurale Komplikationen bei der Katheterablation von
                          Vorhofflimmern bei  unterschiedlichem Antikoagulationsmanagement        
                          H.-F. Vöhringer (Berlin)
 
12:40                Schlusswort
                          B. Gerecke (Göttingen)                       
                          Im Anschluss weitere Diskussionen bei einem Imbiss

14:00                DVFK-Mitgliederversammlung

REFERENTEN UND GÄSTE:

• Dr. Marcel Anssar, Herz-, Thorax- und Gefäßchirurgie, Klinikum Braunschweig
• Prof. Dr. Rüdiger Becker, I. Medizinische Klinik, Klinikum Wolfsburg
• Prof. Dr. Thomas Budde, Klinik für Klinik für Kardiologie, Elektrophysiologie, 
  Gastroenterologie und Innere Medizin, Alfried Krupp Krankenhaus, Essen
• Prof. Dr. Rolf Engberding, AMO Medizinisches Versorgungszentrum, Klinikum Wolfburg/Vietnamese German Academy for Science and Education in Cardiology and Cardiovascular Surgery (VGAC)
• PD Dr. Wolfgang Fehske, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln
• Dr. Birgit Gerecke, Universitätsmedizin Göttingen, Universitäres Herzzentrum
• PD Dr. Wolfgang Harringer, Herz-Thorax- und Gefäßchirurgie, Klinikum Braunschweig
• Prof. Dr. Volker Klauss, Kardiologie Innenstadt, München
• Dr. Dinh Quang Nguyen, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln
• Dr. Si Huyen Nguyen, Prof. für Innere Medizin und Intensivmedizin der Med. Universität PNT, HCM City, Med. Klinik II, Kardiologie, HELIOS St. Marienberg Klinik Helmstedt
• Prof. Dr. Dang Van Phuoc, President of Vietnam Heart Association HCMC
• Prof. Dr. Hubert Seggewiß, em. Chefarzt am Leopoldina Krankenhaus Schweinfurt
• Prof. Dr. Jürgen Tebbenjohanns, Kardiologie, Helios Klinikum Hildesheim
• Prof. Hans-Friedrich Vöhringer,  em. Chefarzt der Medizinischen Klinik I der DRK Kliniken Berlin Köpenick
• Dr. Stefan Winter, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln

SPONSOREN DER TAGUNG:
Bayer Vital GmbH (1000 €), Biotronik Vertriebs GmbH & Co.KG (500 €), Daiichi-Sankyo Deutschland GmbH (1000 €), Novartis Pharma GmbH (700 €), Medtronic GmbH (300 €) 
Stand 08/18

VIETNAMESE GERMAN SCIENTIFIC SYMPOSIUM HUE 2017

20 Years Anniversary of the German Vietnamese Association of Cardiology (DVFK)
01.12.2017
 
Venue: Hue University of Medicine and Pharmacy
Time: 8:00 – 13:00

Organization:
 
. Hue University of Medicine and Pharmacy
. Vietnamese Heart Association Thua Thien Hue
. German Vietnamese Association of Cardiology/ Deutsch-Vietnamesischer Förderkreis für 
  Kardiologie e.V. (DVFK)
. Vietnamese German Academy for Science and Education in Cardiology and
  Cardiovascular Surgery (VGAC)
 
 
Lectures:
 
Echocardiography in oncological diseases
Dr. Irmtraut Kruck, Cardiology Clinic, Ludwigsburg, Germany

Echocardiography for early detection of cardio toxicity in cancer-patients chemotherapy induces impairment of LV- and RV structure, function and mechanics by different complex mechanism. For this comprehensive assessment of LV/RV structure function and mechanics is necessary in cancer patients before, during and after treatment.
Echocardiography is the best image modality because of its availability in every day clinical practice and allows early detection of reduced LV- and RV-function. Therefore it is necessary to perform an echocardiographic examination including all available technics (pulsed and tissue Doppler and 2-D-Strain) in echocardiographic laboratories which have the appropriate equipment and diagnostic expertise. Cardiac dysfunction caused by cardiotoxic treatment can appear at any time during or after therapy and sometimes even after years. Recommendations on the frequency of standardized follow-up examinations exist, but they vary between the specialist societies. Increased morbidity and mortality due to cardiotoxic treatment are now well known, but still too few patients undergo appropriate examinations. Early detection and treatment of existing heart failure and treatment should improve the clinical outcome of these patients.

Beyond coronary angiography: Why do we need additional invasive techniques?
Prof.Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany
 
The decision for interventional treatment of a coronary lesion should be based on symptoms and prove of ischemia. However, in clinical practice, stenoses are often treated depending on the angiographic image, because symptoms are not clear and tests for ischemia have not been performed or the tests are inconclusive. By means of intracoronary pressure measurements (i.e. determination of fractional flow reserve – FFR,  or instantaneous wave-free ratio - iFR) the hemodynamic relevance of a coronary stenoses can be determined during coronary angiography especially in intermediate lesions and thus the decision to treat or not to treat is based on an objective test of ischemia.
Regarding coronary morphology angiography is the standard for imaging of the coronary tree. However, this technique has limitations. Intravascular ultrasound (IVUS) allows a cross-sectional view of the coronary arteries. IVUS may help to diagnose and assess stent underexpansion and malapposition and to guide interventions in complex cases.
Another recent modality based on infrared light is the optical coherence tomography (OCT)with a resolution better than IVUS. It is now used for evaluation of new stent technologies i.e. bioabsorbable scaffolds.

Transcatheter treatment of severe mitral regurgitation using the mitraclip system
Prof. Dr. Florian Krötz, Clinic Starnberg, Department of Cardiology, 82319 Starnberg, Germany

The interventional treatment of mitral valve regurgitation using the MitraClip procedure is a valuable tool for treatment of inoperable patients or patients at high operative risk. Its efficiency in reducing mitral regurgitation has been proven in the EVEREST II study, and use of the technique has rapidly grown worldwide and especially in Germany since then. In suitable patients the method is excellent for treating primary mitral valve regurgitation but has also great potential in patients with heart failure and secondary mitral valve regurgitation, which often show poor outcomes following surgery.
Current recommendations and clinical data concerning the method rely largely on data from the EVEREST II trial. Registries, like the German TRAMI register however, survey a large number of patients, so today there is a good insight into the prerequisites of building an interventional mitral valve program, the need for specialized screening of patients, and for a dedicated interventional setup during implantation. This and the essential procedural techniques will be outlined.
 
Catheter Ablation of Atrial Fibrillation in Patients with heart Failure: Evidence for prognostic indication?
Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

Catheter Ablation of Atrial fibrillation is well established in symptomatic patients. But it is still a symptomatic indication.
In Patients with reduced LV ejection fraction and heart failure, the success rate of catheter ablation remains challenging and controversial.
This presentation gives an update in publications and highlights a new published randomized study (Castle-AF), which has shown a prognostic benefit of catheter ablation in Patients with heart failure.
 
Diagnostic value of cardiac MRI in patients with heart failure
Dr. Birke Schneider, Lübeck, Germany

Heart Failure (HF) is a clinical syndrome characterized by typical symptoms and clinical signs which are caused by a structural and/ or functional cardiac abnormality, resulting in reduced cardiac output and/ or elevated intracardiac pressures at rest or during stress.
Demonstration of an underlying cardiac cause is central to the diagnosis of HF. This is usually a myocardial abnormality causing systolic and/or diastolic ventricular dysfunction. However, abnormalities of the valves, pericardium, endocardium, heart rhythm and conduction can also cause HF, and more than one abnormality is often present. Identification of the underlying cardiac problem is crucial for therapeutic reasons, as the precise pathology determines the specific treatment used.
Cardiac imaging plays a central role in the diagnosis of HF and in guiding treatment. Of several imaging modalities available, echocardiography is the method of choice in patients with suspected HF, for reasons of accuracy, availability (including portability), safety and cost. However, the reliability of the echocardiographic study is highly dependent on the operator and centre experience and the image quality. Transthoracic echocardiography (TTE) nevertheless is regarded the primary method for assessment of systolic and diastolic function of both left and right ventricles and for the evaluation of valvular function.
Cardiac magnetic resonance imaging (CMRI) is nowadays acknowledged as the gold standard for the measurements of volumes, mass and ejection fraction of both the left and right ventricles (Class I Level C in the ESC Guidelines on HF 2016). It is the best alternative cardiac imaging modality for patients with nondiagnostic echocardiographic studies (particularly for imaging of the right heart) and is the method of choice in patients with complex congenital heart diseases.
In addition, CMRI also allows tissue characterization and thereby can be useful for establishing HF aetiology. CMRI is the preferred imaging method to assess myocardial fibrosis using late gadolinium enhancement (LGE) along with T1 mapping. CMRI with LGE allows differentiation between ischaemic and non-ischaemic origins of HF and myocardial fibrosis/ scars can be visualized. Different hyperenhancement patterns result from the pathophysiology of the underlying disease and help to establish the correct diagnosis. CMRI may also be used for the assessment of myocardial ischaemia and viability in patients with HF and coronary artery disease.
Various patients are presented where CMRI was essential in finding the cause of HF and had implications for patient management. Clinical limitations of CMRI will also be discussed.
 
Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents
Prof. Dr. Hans-F. Voehringer, DRK Clinics Berlin, Germany

Surgeons, cardiologists, primary care physicians, and anesthesiologists frequently have to determine the antiplatelet management in patients with coronary heart disease undergoing elective surgery. In Germany, more than 300 000 patients receive coronary stents annually, with up to 20% of these individuals requiring non-cardiac surgery within 2 years. There is definitive evidence that patients who have undergone percutaneous coronary interventions with stent implantation are at increased risk of perioperative major cardiac events (MACE) and that the risk is moderated by stent type (bare metal stent [BMS] vs. drug eluting stent [DES]), operative urgency, early discontinuation of antiplatelet therapy, and time from coronary intervention.
Guidelines recommend delaying non-cardiac surgery in patients after coronary stent procedure for 1 year after DES and for 6 weeks after BMS. The evidence underlying these recommendations is limited and conflicting. In a systematic review the perioperative antiplatelet management will be assessed to help clinicians with this common clinical case.
 
3D Echocardiography, from research to routine application: Today an obligatory application for a comprehensive investigation of the heart
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

A comprehensive investigation of systolic and diastolic heart failure patients by echocardiography
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Left atrial function, what can we derive from echocardiographic examinations with special respect to prognosis of stability after electrophysiological ablation for atrial  fibrillation
Mareike Juliana Brunold, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Real world experience with resynchronization therapy: A detailed overview of more than 400 consecutive patients treated according to the guidelines
Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Sudden cardiac death beyond the existing guidelines: Does the Life Vest concept opens better solutions for our patients?  
Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
FACULTY:
Dr. Mareike Juliana Brunold, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany
Prof. Dr. Florian Krötz, Clinic Starnberg, Department of Cardiology, 82319 Starnberg, Germany
Dr. Irmtraut Kruck, Cardiology Clinic Ludwigsburg, Germany
Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at Pham Ngoc Thach University HCMC,  HELIOS St. Marienberg Hospital Helmstedt, Germany
Dr. Birke Schneider, MD, Lübeck, Germany
Prof. Dr. Hans-F. Voehringer, DRK Clinics Berlin, Germany
Dr. Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

Ehrenplakette für Prof. Si Huyen Nguyen (HCMC/Helmstedt) und Prof. Volker Klauss (München), überreicht vom Herrn Nguyen Van Phuong, stellvertretenden Gouverneur von Thua Thien-Hue

Prof. F. Krötz (Starnberg)

Prof. V. Klauss (München) bei der HKU mit dem Ärzteteam der Universität Hue 

Gruppenbild mit Prof. V. Klauss. An der rechten Seite von Prof. Klauss ist Prof. H.A. Tien, Leiter des HKLs der Universitätsklinik Hue.

 VIETNAMESE GERMAN SCIENTIFIC SYMPOSIUM 2017
Nha Trang/Khanh Hoa 28.11.2017

20 Years Anniversary 
of the German Vietnamese Association of Cardiology
(DVFK)

Venue: KHANH HOA HOSPITAL
Time: 13:30 – 17:00
 
Organization:
. Vietnamese Heart Association Khanh Hoa
. Khanh Hoa Hospital
. German Vietnamese Association of Cardiology/ Deutsch-Vietnamesischer Förderkreis für  
  Kardiologie e.V. (DVFK)
. Vietnamese German Academy for Science and Education in Cardiology and
  Cardiovascular Surgery (VGAC)
. Vietnamese German Faculty of Medicine of Pham Ngoc Thach University of Medicine at
  Ho Chi Minh City (VGFM)
 
Lectures:
 
Echocardiography in oncological diseases
Dr. Irmtraut Kruck, Cardiology Clinic, Ludwigsburg, Germany

Echocardiography for early detection of cardio toxicity in cancer-patients chemotherapy induces impairment of LV- and RV structure, function and mechanics by different complex mechanism. For this comprehensive assessment of LV/RV structure function and mechanics is necessary in cancer patients before, during and after treatment.
Echocardiography is the best image modality because of its availability in every day clinical practice and allows early detection of reduced LV- and RV-function. Therefore it is necessary to perform an echocardiographic examination including all available technics (pulsed and tissue Doppler and 2-D-Strain) in echocardiographic laboratories which have the appropriate equipment and diagnostic expertise. Cardiac dysfunction caused by cardiotoxic treatment can appear at any time during or after therapy and sometimes even after years. Recommendations on the frequency of standardized follow-up examinations exist, but they vary between the specialist societies. Increased morbidity and mortality due to cardiotoxic treatment are now well known, but still too few patients undergo appropriate examinations. Early detection and treatment of existing heart failure and treatment should improve the clinical outcome of these patients.

Beyond coronary angiography: Why do we need additional invasive techniques?
Prof.Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany
 
The decision for interventional treatment of a coronary lesion should be based on symptoms and prove of ischemia. However, in clinical practice, stenoses are often treated depending on the angiographic image, because symptoms are not clear and tests for ischemia have not been performed or the tests are inconclusive. By means of intracoronary pressure measurements (i.e. determination of fractional flow reserve – FFR,  or instantaneous wave-free ratio - iFR) the hemodynamic relevance of a coronary stenoses can be determined during coronary angiography especially in intermediate lesions and thus the decision to treat or not to treat is based on an objective test of ischemia.
Regarding coronary morphology angiography is the standard for imaging of the coronary tree. However, this technique has limitations. Intravascular ultrasound (IVUS) allows a cross-sectional view of the coronary arteries. IVUS may help to diagnose and assess stent underexpansion and malapposition and to guide interventions in complex cases.
Another recent modality based on infrared light is the optical coherence tomography (OCT)with a resolution better than IVUS. It is now used for evaluation of new stent technologies i.e. bioabsorbable scaffolds.

Transcatheter treatment of severe mitral regurgitation using the mitraclip system
Prof. Dr. Florian Krötz, Clinic Starnberg, Department of Cardiology, 82319 Starnberg, Germany
The interventional treatment of mitral valve regurgitation using the MitraClip procedure is a valuable tool for treatment of inoperable patients or patients at high operative risk. Its efficiency in reducing mitral regurgitation has been proven in the EVEREST II study, and use of the technique has rapidly grown worldwide and especially in Germany since then. In suitable patients the method is excellent for treating primary mitral valve regurgitation but has also great potential in patients with heart failure and secondary mitral valve regurgitation, which often show poor outcomes following surgery.
Current recommendations and clinical data concerning the method rely largely on data from the EVEREST II trial. Registries, like the German TRAMI register however, survey a large number of patients, so today there is a good insight into the prerequisites of building an interventional mitral valve program, the need for specialized screening of patients, and for a dedicated interventional setup during implantation. This and the essential procedural techniques will be outlined.
 
Catheter Ablation of Atrial Fibrillation in Patients with heart Failure: Evidence for prognostic indication?
Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

Catheter Ablation of Atrial fibrillation is well established in symptomatic patients. But it is still a symptomatic indication.
In Patients with reduced LV ejection fraction and heart failure, the success rate of catheter ablation remains challenging and controversial.
This presentation gives an update in publications and highlights a new published randomized study (Castle-AF), which has shown a prognostic benefit of catheter ablation in Patients with heart failure.
 
Diagnosis and Management of patients with inherited primary arrhythmia syndromes
Risk stratification in a family with Long QT-Syndrome
Dr. Birgit Gerecke, outpatient center cardiology Peine

When the diagnosis of an inherited primary arrhythmia syndrome is made, considerations on the management also of other family members are required. This is shown exemplary in a family with LQTS.
A 16 year old girl presented with recurrent syncope. The examinations of the family doctor contained an ECG. A prolongation of the QT interval was seen without a secondary cause of QT prolongation. The patient was admitted to a hospital. ECG monitoring showed runs of torsades de pointes VT. Beta blocker therapy was initiated, but still runs of VT were present. The diagnosis of a LQTS 2 was established. Family history revealed a sudden cardiac death in a great uncle of the index patient. ICD implantation was discussed and after informed consenta single chamber ICD system was implanted. Till now there has been no adequate shock delivery in the patient.
ECGs of the parents and two siblings were done. The mother also presented with a QT prolongation, but till now is asymptomatic. A younger sister has a borderline QTc, the ECG of the brother showed a normal QTc.
Genetic testing was done in the family with the presence of an LQTS gene mutation (KCNH2mutation) in the index patient. This mutation was also found in her mother, but not in the siblings.
LQT-Syndrom is an inherited arrhythmia syndrome with a broad spectrum of clinical presentations, even in one family. A family based genetic testing can help to stratify the management. An exclusion of an assured mutation of the index patient in other family members can rule out the risk of a rhythmogenic disease and event with a high probability. Life style changes are recommended for family members with the mutation containing the avoidance of QT prolonging drugs, the identification and correction of electrolyte abnormalities, beta-blockers or ICD-implantation depending on the clinical presentation. Approximately 20-25 % of patients with LQTS confirmed by the presence of an LQTS gene mutation may have a normal QTc. Provocative tests with QT measurement e.g. in the recovery phase of exercise testing can help to unmask these patients.
 
Diagnostic value of cardiac MRI in patients with heart failure
Dr. Birke Schneider, Lübeck, Germany

Heart Failure (HF) is a clinical syndrome characterized by typical symptoms and clinical signs which are caused by a structural and/ or functional cardiac abnormality, resulting in reduced cardiac output and/ or elevated intracardiac pressures at rest or during stress.
Demonstration of an underlying cardiac cause is central to the diagnosis of HF. This is usually a myocardial abnormality causing systolic and/or diastolic ventricular dysfunction. However, abnormalities of the valves, pericardium, endocardium, heart rhythm and conduction can also cause HF, and more than one abnormality is often present. Identification of the underlying cardiac problem is crucial for therapeutic reasons, as the precise pathology determines the specific treatment used.
Cardiac imaging plays a central role in the diagnosis of HF and in guiding treatment. Of several imaging modalities available, echocardiography is the method of choice in patients with suspected HF, for reasons of accuracy, availability (including portability), safety and cost. However, the reliability of the echocardiographic study is highly dependent on the operator and centre experience and the image quality. Transthoracic echocardiography (TTE) nevertheless is regarded the primary method for assessment of systolic and diastolic function of both left and right ventricles and for the evaluation of valvular function.
Cardiac magnetic resonance imaging (CMRI) is nowadays acknowledged as the gold standard for the measurements of volumes, mass and ejection fraction of both the left and right ventricles (Class I Level C in the ESC Guidelines on HF 2016). It is the best alternative cardiac imaging modality for patients with nondiagnostic echocardiographic studies (particularly for imaging of the right heart) and is the method of choice in patients with complex congenital heart diseases.
In addition, CMRI also allows tissue characterization and thereby can be useful for establishing HF aetiology. CMRI is the preferred imaging method to assess myocardial fibrosis using late gadolinium enhancement (LGE) along with T1 mapping. CMRI with LGE allows differentiation between ischaemic and non-ischaemic origins of HF and myocardial fibrosis/ scars can be visualized. Different hyperenhancement patterns result from the pathophysiology of the underlying disease and help to establish the correct diagnosis. CMRI may also be used for the assessment of myocardial ischaemia and viability in patients with HF and coronary artery disease.
Various patients are presented where CMRI was essential in finding the cause of HF and had implications for patient management. Clinical limitations of CMRI will also be discussed.
 
Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents
Prof. Dr. Hans-F. Voehringer, DRK Clinics Berlin, Germany

Surgeons, cardiologists, primary care physicians, and anesthesiologists frequently have to determine the antiplatelet management in patients with coronary heart disease undergoing elective surgery. In Germany, more than 300 000 patients receive coronary stents annually, with up to 20% of these individuals requiring non-cardiac surgery within 2 years. There is definitive evidence that patients who have undergone percutaneous coronary interventions with stent implantation are at increased risk of perioperative major cardiac events (MACE) and that the risk is moderated by stent type (bare metal stent [BMS] vs. drug eluting stent [DES]), operative urgency, early discontinuation of antiplatelet therapy, and time from coronary intervention.
Guidelines recommend delaying non-cardiac surgery in patients after coronary stent procedure for 1 year after DES and for 6 weeks after BMS. The evidence underlying these recommendations is limited and conflicting. In a systematic review the perioperative antiplatelet management will be assessed to help clinicians with this common clinical case.

A comprehensive investigation of systolic and diastolic heart failure patients by echocardiography
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Left atrial function, what can we derive from echocardiographic examinations with special respect to prognosis of stability after electrophysiological ablation for atrial  fibrillation
Mareike Juliana Brunold, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
Sudden cardiac death beyond the existing guidelines: Does the Life Vest concept opens better solutions for our patients?
Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
 
 
FACULTY:
Dr. Mareike Juliana Brunold, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
PD Dr. Wolfgang Fehske, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
Dr. Birgit Gerecke, outpatient center cardiology Peine, Germany
Prof. Dr. Volker Klauss, Cardiology Munich City Centre, Munich, Germany
Prof. Dr. Florian Krötz, Clinic Starnberg, Department of Cardiology, 82319 Starnberg, Germany
Dr. Irmtraut Kruck, Cardiology Clinic Ludwigsburg, Germany
Dr. Dinh Quang Nguyen, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 
Prof. Dr. Si Huyen Nguyen, Vietnamese German Faculty of Medicine at Pham Ngoc Thach University HCMC,  HELIOS St. Marienberg Hospital Helmstedt, Germany
Dr. Birke Schneider, MD, Lübeck, Germany
Prof. Dr. Hans-F. Voehringer, DRK Clinics Berlin, Germany
Stefan Winter, Medical Clinic III, Department of Cardiology, St. Vinzenz-Hospital, Cologne, Germany 

Visite auf einer Station der kardiologischen Abteilung

v.l. S. Klauss (München), Dr. I. Kruck (Ludwigsburg), Dr. B. Gerecke (Peine), Dr. M.J. Brunold (Köln), Dr. B. Schneider (Lübeck)

17. VIETNAMESE GERMAN HEART DAYS HCMC
26.11.2017
Venue: NEW WORLD HOTEL, 76 Le Lai Street, District 1, HCMC
​Time: 08:30 - 16:30

Organization:
HCMC Cardiovascular Association
in Cooperation with

• Deutsch-Vietnamesischer Förderkreis für Kardiologie e.V. (DVFK)/German Vietnamese Association of Cardiology
• Vietnamese German Academy for Science and Education in Cardiology and Cardiovascular Surgery (VGAC)
• Vietnamese German Faculty of Medicine (VGFM) of the Pham Ngoc Thach University HCMC (PNTU)
• Tam Duc Hospital

 Echokardiographie bei onkologischen Erkrankungen (Dr. Irmtraut Kruck/Ludwigsburg)

21. DVFK-JAHRESTAGUNG IN BRAUNSCHWEIG
Datum:                    02.09.2017
Ort:                           Ärztehaus, An der Petrikirche 1, 38100 Braunschweig
               
                                               AKTUELLE KARDIOLOGIE &
                                INTERESSANTE KASUISTIKEN

PROGRAMM:
8.30 Eröffnung:      S.H. Nguyen, Präsident DVFK / Helmstedt
8.40 Begrüßung:    M. C. Renneberg, Vizepräsidentin der Ärztekammer Niedersachsen (ÄKN) und Vorsitzende der ÄKN                                           Bezirksstelle Braunschweig
                                   D.V. Phuoc, President of Vietnam Heart Association HCMC
8.55 Einleitung:      R. Engberding, Präsident VGAC/Wolfsburg           
 
I. Sitzung:              Kardiologie in Kooperationen
Vorsitz:                      R. Engberding (Wolfsburg), W. Harringer (Braunschweig)

09:00                         Echokardiographie bei onkologischen Erkrankungen
                                   I.Kruck (Ludwigsburg)
09:20                         Interdisziplinäres Konzept bei TAVI und Aortenchirurgie
                                   im Hybrid-OP
                                   Chronische Herzinsuffizienz: eine interdisziplinäre Herausforderung
                                   W. Harringer / M. Anssar (Braunschweig)
09:40                         Akuttherapie des ischämischen Schlaganfalls
                                   L. Harms (Berlin)
 
II.Sitzung:              Diagnostik in der Kardiologie
Vorsitz:                      B. Gerecke (Peine) / W. Fehske (Köln)

10:00                         Kardiale MRT-Diagnostik bei Herzinsuffizienz
                                   B. Schneider (Lübeck)
10:20                        „Der wahre und der falsche Mobitz - warum in Deutschland so viele Herzschrittmacher                                                        implantiert werden“         
                                   K. von Olshausen (Heidelberg)
10:40                         Gendiagnostik bei kardiovaskulären Erkrankungen: Stand 2017
                                   B. Gerecke (Peine)
 
11:00                         Pause
 
III.Sitzung:            Interessante Kasuistiken
Vorsitz:                     GD Kneissl (Mainz) / W-K. Diederich (Helmstedt)

11.30                        Patient mit ventrikulärer Tachykardie                      
                                  L. Lichtenberg (Köln)
11:50                        Vorhofflimmern und Herzinsuffizienz
                                  D. Q. Nguyen (Köln)                  
12:10                        Pat. mit chronischem Koronarverschluss
                                  C. Fleischmann (Wolfsburg)
 
12:30                        Schlusswort
                                  B. Gerecke (Peine)
                                  Im Anschluss weitere Diskussionen bei einem Imbiss
 
14:00                        DVFK-Mitgliederversammlung 
 

REFERENTEN UND GÄSTE:

• Dr. Marcel Anssar, Herz-, Thorax- und Gefäßchirurgie, Klinikum Braunschweig
• Dr. Klaus-Werner Diederich, Med. Klinik II,  invasive Kardiologie, HELIOS St. Marienberg Klinik Helmstedt 
• Prof. Dr. Rolf Engberding, AMO Medizinisches Versorgungszentrum, Klinikum Wolfburg/Vietnamese German Academy for Science and Education in Cardiology and Cardiovascular Surgery (VGAC)
• PD Dr. Wolfgang Fehske, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln
• Dr. Claus Fleischmann, Med. Klinik I, Klinikum  Wolfsburg
• Dr. Birgit Gerecke, MVZ Ambulantes Kardiologisches Zentrum Peine
• PD Dr. Wolfgang Harringer, Herz-,Thorax- und Gefäßchirurgie, Klinikum Braunschweig
• Prof. Dr. Lutz Harms, Charité- Universitätsmedizin, Klinik für Neurologie mit Experimenteller Neurologie, Berlin
• Prof. Dr. Volker Klauss, Kardiologie Innenstadt, München
• Prof. Dr. Georg D. Kneissl,  Vietnamese German Faculty of Medicine of University Pham Ngoc Thach/Ho Chi Minh City, Universitätsmedizin Mainz
• Dr. Irmtraut Kruck, Kardiologische Gemeinschaftspraxis, Ludwigsburg
• Dr. Lutz Lichtenberg, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln
• Dr. Si Huyen Nguyen, Prof. für Innere Medizin und Intensivmedizin der Med. Universität PNT, HCM City, Med. Klinik II, Kardiologie, HELIOS St. Marienberg Klinik Helmstedt
• Dr. Dinh Quang Nguyen, Innere Medizin III/Kardiologie, St.Vinzenz Hospital Köln
• Prof. Dr. Klaus von Olshausen, Heidelberg
• Prof. Dr. Dang Van Phuoc, President of Vietnam Heart Association HCMC
• Marion Charlotte Renneberg, Vizepräsidentin der Ärztekammer Niedersachsen (ÄKN) und Vorsitzende der ÄKN Bezirksstelle Braunschweig
• Dr. Birke Schneider, Med. Klinik II, Kardiologie und Angiologie, Sana Kliniken Lübeck

SPONSOREN DER TAGUNG:
Bayer Vital GmbH (1000 €), Biotronik Vertriebs GmbH & Co.KG (500 €), Boehringer Ingelheim Pharma GmbH & Co.KG (500 €), Daiichi-Sankyo Deutschland GmbH (750 €), Medtronic GmbH (300 €),  Novartis Pharma GmbH (700 €), SERVIER Deutschland GmbH (500 €)

Grußwort von Prof. Dang Van Phuoc, Präsident der kardiologischen Gesellschaft der Ho-Chi-Minh-Stadt